The DOI matches its Crossref record.
Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis
Abstract
Following chronic liver injury of any etiology, there is progressive fibrosis. To date, removing the causative agent is the only effective therapy to stop or even reverse liver fibrosis. Therefore, the development of effective antifibrotic therapies represents a challenge for modern hepatology. In the past decade, dramatic advances have been made in the understanding of the cellular and molecular mechanisms underlying liver fibrogenesis. The identification of activated hepatic stellate cells (HSCs) as the major fibrogenic cell type in the injured liver, as well as the recognition of key cytokines involved in this process, have facilitated the design of promising new antifibrotic therapies. These therapies are aimed at inhibiting the accumulation of activated HSCs at the sites of liver injury and preventing the deposition of extracellular matrix. Although many of these approaches are effective in experimental models of liver fibrosis, their efficacy and safety in humans are still unknown. This review describes the current therapeutic approaches for liver fibrosis and discusses different features of activated HSCs as a target to design new treatments to inhibit scar formation in chronic liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationLiver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Gressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718
“The cell types participating in fibrogenesis, the fibrogenic mediators and, hence, the potential targets of antifibrotic trials are almost identified and promise therapeutic success in the not too distant future [7, 8].”
BackgroundPaik, Y.-H., Schwabe, R. F., Bataller, R., Russo, M. P., Jobin, C., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50182 · Cited by 651
Self-citationPathogenesis of liver cirrhosis
Zhou, W.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7312 · Cited by 627
Bataller, R., Schwabe, R. F., Choi, Y. H., Yang, L., Paik, Y. H., Lindquist, J., Qian, T., Schoonhoven, R., Hagedorn, C. H., Lemasters, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18212 · Cited by 548
Self-citationMechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
Jou, J., Choi, S., & Diehl, A. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091981 · Cited by 482
Noninvasive assessment of liver fibrosis
Martínez, S. M., Crespo, G., Navasa, M., & Forns, X. (2011) · Hepatology · doi:10.1002/hep.24013 · Cited by 422
Reversal of Hepatic Fibrosis — Fact or Fantasy?
Friedman, S. L., & Bansal, M. B. (2006) · Hepatology · doi:10.1002/hep.20974 · Cited by 379
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Genetic Polymorphisms and the Progression of Liver Fibrosis: A Critical Appraisal
Bataller, R., North, K. E., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50127 · Cited by 355
Self-citationBataller, R., Sancho-bru, P., Ginès, P., Lora, J. M., Al-garawi, A., Solé, M., Colmenero, J., Nicolás, J. M., Jiménez, W., Weich, N., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00695-4 · Cited by 352
Self-citationPlatelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
Campbell, J. S., Hughes, S. D., Gilbertson, D. G., Palmer, T. E., Holdren, M. S., Haran, A. C., Odell, M. M., Bauer, R. L., Ren, H.-P., Haugen, H. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409722102 · Cited by 333
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
CARPINO, G., MORINI, S., GINANNICORRADINI, S., FRANCHITTO, A., MERLI, M., SICILIANO, M., GENTILI, F., ONETTIMUDA, A., BERLOCO, P., & ROSSI, M. (2005) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.11.009 · Cited by 309
Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis
Kisseleva, T., & Brenner, D. A. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04658.x · Cited by 286
Self-citationHepatic stellate cells and the reversal of fibrosis
Kisseleva, T., & Brenner, D. A. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04584.x · Cited by 278
Self-citationP38 Mapk Mediates Fibrogenic Signal Through Smad3 Phosphorylation in Rat Myofibroblasts
Furukawa, F., Matsuzaki, K., Mori, S., Tahashi, Y., Yoshida, K., Sugano, Y., Yamagata, H., Matsushita, M., Seki, T., Inagaki, Y., et al. (2003) · Hepatology · doi:10.1002/hep.1840380414 · Cited by 265
Bataller, R., Paik, Y.-H., Lindquist, J. N., Lemasters, J. J., & Brenner, D. A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.018 · Cited by 252
Self-citationThe extracellular matrix and insulin resistance
Williams, A. S., Kang, L., & Wasserman, D. H. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.05.006 · Cited by 228
Yu, C., Wang, F., Jin, C., Huang, X., Miller, D. L., Basilico, C., & McKeehan, W. L. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63522-5 · Cited by 167
“The chronic activation of nonparenchymal HSCs (also called Ito cells and fat-storing cells) has been established as the major contributor to liver fibrogenesis resulting from chronic toxic insult primarily through its production of extracellular matrix components and collagen 1(I), in particular.(29,39) Multiple cytok…”
BackgroundIn Vivo Immune Modulatory Activity of Hepatic Stellate Cells in Mice
Chen, C.-H., Kuo, L.-M., Chang, Y., Wu, W., Goldbach, C., Ross, M. A., Stolz, D. B., Chen, L., Fung, J. J., Lu, L., et al. (2006) · Hepatology · doi:10.1002/hep.21379 · Cited by 154
PAI‐1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA
Wang, H., Zhang, Y., & Heuckeroth, R. O. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.049 · Cited by 98
MAREK, C. J., TUCKER, S. J., KONSTANTINOU, D. K., ELRICK, L. J., HAEFNER, D., SIGALAS, C., MURRAY, G. I., GOODWIN, B., & WRIGHT, M. C. (2005) · Biochemical Journal · doi:10.1042/bj20041598 · Cited by 89
Gene expression in Peyronie's disease
Gonzalez-Cadavid, N. F., Magee, T. R., Ferrini, M., Qian, A., Vernet, D., & Rajfer, J. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900873 · Cited by 84
GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells
Arroyo, N., Villamayor, L., Díaz, I., Carmona, R., Ramos-Rodríguez, M., Muñoz-Chápuli, R., Pasquali, L., Toscano, M. G., Martín, F., Cano, D. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150059 · Cited by 60
“In response to liver injury, HSCs get activated, acquiring proliferative and contractile features and become myofibroblast-like cells that express α-smooth muscle actin (α-SMA) and synthesize ECM components such as collagen and laminin (2).”
Maubach, G., Lim, M. C. C., Kumar, S., & Zhuo, L. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.005 · Cited by 46
Li, Y., Kim, B.-G., Qian, S., Letterio, J. J., Fung, J. J., Lu, L., & Lin, F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500139 · Cited by 45
Insulin‐like growth factor binding protein‐related protein 1 contributes to hepatic fibrogenesis
Guo, X. H., Liu, L. X., Zhang, H. Y., Zhang, Q. Q., Li, Y., Tian, X. X., & Qiu, Z. H. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12126 · Cited by 39
Metadata
- Authors
- Bataller, R., & Brenner, D. A.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 21
- Issue
- 03
- Pages
- 437-452
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2041587548
- Cited by
- 492
- References
- 0
- FWCI
- 16.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.